Schrödinger, Inc.

{{Infobox company

| logo =

| name = Schrödinger, Inc.

| type = Public

| traded_as = {{NASDAQ|SDGR}}
Russell 2000 Component
S&P 600 Component

| foundation = {{start date and age|1990}}

| founder = Richard A. Friesner,
William A. Goddard III

| location = New York, New York

| key_people = Ramy Farid (president & CEO)
Michael Lynton (chairman)

| industry = {{flatlist|

}}

| area_served = Worldwide

| products = {{flatlist|

Advanced computational platform for drug discovery and materials science
LiveDesign
PyMOL

}}

| num_employees = 1015

| revenue = {{Increase}} $217 Million (2023){{Cite press release |title=Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results |url=https://ir.schrodinger.com/press-releases/news-details/2024/Schrdinger-Reports-Strong-Fourth-Quarter-and-Full-Year-2023-Financial-Results/default.aspx |website=ir.schrodinger.com |access-date=2 Feb 2024 |language=en-us |url-status=live}}

| homepage = {{URL|https://schrodinger.com/}}

}}

Schrödinger, Inc. is an international scientific software and biotechnology company that specializes in developing computational tools and software for drug discovery and materials science.

Schrödinger's software is used by pharmaceutical companies, biotech firms, and academic researchers to simulate and model the behavior of molecules at the atomic level. This accelerates the design and develops new drugs and materials more efficiently, reducing the time and cost of bringing them to market.

Schrödinger's software tools include molecular dynamics simulations, free energy calculations, quantum mechanics calculations, and virtual screening tools. The company also offers consulting services and collaborates with partners in the industry to advance the field of computational chemistry and drug discovery.

Products and services

Schrödinger's computational platforms evaluate compounds in silico, with experimental accuracy on properties such as binding affinity and solubility. The company's products include molecular modeling programs, and an Enterprise Informatics Platform named LiveDesign, which is intended to facilitate communication among interdisciplinary research teams.{{Cite web|url=https://www.schrodinger.com/livedesign|title=LiveDesign|website=LiveDesign}}

In addition to computational platforms, Schrödinger develops custom software for enterprises, as well as training, computer-cluster design and implementation, and research-based drug discovery projects.{{cite web |last=Booth |first=Bruce |date=June 27, 2013 |title=The Nimbus Experiment: Structure-Based Drug Deals |url=https://www.forbes.com/sites/brucebooth/2013/06/27/the-nimbus-experiment-structure-based-drug-deals/ |website=Forbes}}{{cite press release |url=http://www.marketwatch.com/story/schrodinger-and-professor-mark-e-thompson-usc-announce-research-collaboration-to-enable-computeraided-design-of-organic-semiconductor-materials-2013-06-27/ |title=Schrodinger and Professor Mark E. Thompson (USC) Announce Research Collaboration to Enable Computer'Aided Design of Organic Semiconductor Materials |date=June 2013 |access-date=20 October 2014}}

Schrödinger software licenses are available to academic institutions for education and not-for-profit research.{{Cite web |title=Academic Site License |url=https://www.schrodinger.com/life-science/use-cases/academic-site-license/ |access-date=2024-12-06 |website=Schrödinger |language=en-US}}

Partners

Schrödinger's partners include pharmaceutical companies, including Bayer,{{Cite press release|url=https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-and-bayer-collaborate-co-develop-de-novo-design|title=Schrödinger and Bayer Collaborate to Co-Develop de novo Design Technology to Accelerate Drug Discovery|date=8 January 2020|website=Schrödinger|access-date=12 March 2021}}{{cite press release |last1=Hillisch |first1=Alexander |title=A Digital Platform for Molecular Design: Inside the Schrödinger-Bayer Collaboration |url=https://extrapolations.com/a-digital-platform-for-molecular-design-inside-the-schrodinger-bayer-collaboration/ |website=extrapolations.com |access-date=15 June 2023 |archive-url=https://web.archive.org/web/20230221192847/https://extrapolations.com/a-digital-platform-for-molecular-design-inside-the-schrodinger-bayer-collaboration/ |archive-date=Feb 21, 2023 |language=en |date=6 January 2022 |url-status=live}} Takeda,{{Cite press release|url=https://www.fiercebiotech.com/cro/takeda-schrodinger-form-multiprogram-drug-discovery-pact|title=Takeda, Schrödinger form multiprogram drug discovery pact|last=Liu|first=Angus|date=July 20, 2017|website=FierceBiotech}} and more.

Nimbus Therapeutics, co-founded by Schrödinger, uses Schrödinger's drug screening and design platform for drug discovery. In 2016, Nimbus Therapeutics sold an Acetyl-CoA carboxylase (ACC) inhibitor designed by Schrödinger to Gilead Sciences in a deal worth up to $1.2 billion.{{Cite press release|last1=Flood|first1=Amy|last2=O’Brien|first2=Patrick|last3=Melone|first3=Liz|url=https://www.businesswire.com/news/home/20160404005324/en/Gilead-Sciences-Announces-Acquisition-Nimbus-Therapeutics%E2%80%99-Acetyl-CoA|title=Gilead Sciences Announces Acquisition of Nimbus Therapeutics' Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases|date=2016-04-04|website=www.businesswire.com|language=en|access-date=2019-06-19}} As of spring 2019 the ACC inhibitor was moving through late-stage clinical trials in non-alcoholic steatohepatitis.{{Cite press release|url=https://www.gilead.com/news-and-press/press-room/press-releases/2019/4/gilead-announces-topline-data-from-phase-3-stellar3-study-of-selonsertib-in-bridging-fibrosis-f3-due-to-nonalcoholic-steatohepatitis-nash|title=Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)|website=www.gilead.com|access-date=2019-06-19}}

Recognition

In November 2013, Schrödinger, in collaboration with Cycle Computing and the University of Southern California, set a record for the world's largest and fastest cloud computing run by using 156,000 cores on Amazon Web Services to screen over 205,000 molecules for materials science research.{{Cite web|url=https://www.cnet.com/news/supercomputing-simulation-employs-156000-amazon-processor-cores/|title=Supercomputing simulation employs 156,000 Amazon processor cores|last=Shankland|first=Stephen|date=November 12, 2013|website=CNet}} That work was a follow-up to a 2012 collaboration which saw Cycle Computing creating a 50,000 core virtual supercomputer using Amazon and Schrödinger's infrastructure; at that time, it was used to analyze 2.1 million compounds in 3 hours.{{Cite web|url=https://arstechnica.com/information-technology/2012/04/4829-per-hour-supercomputer-built-on-amazon-cloud-to-fuel-cancer-research/|title=$4,829-per-hour supercomputer built on Amazon cloud to fuel cancer research|last=Brodkin|first=Jon|date=April 19, 2012|website=Ars Technica}}